

Declaration of Interests Register							
Technology Appraisal Committee A				Publication Date: 02/02/2022			
Topic: ID3776 Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (CDF Review of TA553)							
Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Professor Paul Lorigan	Clinical expert	Direct – financial	Has acted as paid adviser to MSD and other pharmaceutical companies, given lectures and received financial support to attend international meetings.		July 2021		
		Direct – non-financial	Chair of EORTC Melanoma Group which carried out the main trial of pembrolizumab in this indication. Co-author of manuscripts related to this study.  Trustee of Melanoma Focus.		July 2021	N/A	

Link to Committee A interests register : <https://www.nice.org.uk/Get-Involved/Meetings-in-public/Technology-appraisal-Committee/Committee-A-Members>

#### GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

**Relevant dates:** Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.